Imaging Study Using a PET Scan Agent in Blood and Histiocytic Cancers
Tests a PET imaging agent, pentixafor, to see it in lymphoma, myeloma, or histiocytic disorders.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
- Status
- Active, not recruiting
- Phase
- Early phase 1
- People taking part
- 30 people enrolled
- Started
- 1 Oct 2021
- Expected to end
- Oct 2027
- Type of study
- Interventional
- Treatments tested
- [68Ga]-Pentixafor
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with blood cancers such as non-Hodgkin lymphoma, multiple myeloma (or its early forms MGUS/SMM) or histiocytic neoplasms, and also some solid tumors. They will have a [68Ga]-pentixafor PET/CT scan.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Proven blood cancer, either never treated, not responding to treatment, or relapsed. Includes indolent B- or T-cell non-Hodgkin lymphoma or mantle cell lymphoma with measurable disease; histiocytic neoplasms (LCH, ECD, RDD); MGUS, SMM or multiple myeloma; and solid tumors such as lung cancer, meningioma or adrenocortical tumors.
Main reasons for not taking part
- Breast-feeding
- Chronic kidney disease with eGFR<30
- Refusing or unable to tolerate the scan (for example, due to claustrophobia)
- Positive pregnancy test for women who could become pregnant
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:
- Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria; or
- Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD)
- MGUS/SMM or MM according to IMWG definitions
- Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with Cushing's disease
- Age ≥18
- Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \& Guidelines) from assays obtained <2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention
- MSKCC patients
Who cannot take part
- History of renal functional disorders (chronic kidney disease with eGFR<30)
- Breast-feeding
- Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Where in United States
- Memorial Sloan-Kettering Cancer CenterNew York, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
The group in the trial
- [68Ga]-PentixaforTreatment being tested
An intravenous bolus of 3 -5 mCi \[68Ga\]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. \[68Ga\]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). \[68Ga\]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
- Plain-language title
- Imaging Study Using a PET Scan Agent in Blood and Histiocytic CancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 November 2026